Cover Image
市場調查報告書

全球出血性疾病治療市場預測 (2017∼2027年):各適應症 (A型血友病,B型血友病,類血友病病) 、各類藥物,各地區預測與分析

World Bleeding Disorders Treatment Market 2017-2027: Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class and Geography

出版商 Visiongain Ltd 商品編碼 291016
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球出血性疾病治療市場預測 (2017∼2027年):各適應症 (A型血友病,B型血友病,類血友病病) 、各類藥物,各地區預測與分析 World Bleeding Disorders Treatment Market 2017-2027: Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class and Geography
出版日期: 2017年09月15日 內容資訊: 英文 172 Pages
簡介

全球出血性疾病治療市場,預計2017年超越70億美元。該市場預計至2027年達成大幅收益成長。

本報告提供全球出血性疾病治療市場相關調查,今後的收益預測,各適應症、各類藥物、各地區的趨勢,及加入此市場的以及主要企業的簡介等彙整。

第1章 本報告概要

第2章 全球出血性疾病治療市場簡介

第3章 市場預測

第4章 各適應症的預測

  • 概要
  • A型血友病
  • B型血友病
  • 類血友病病
  • 其他

第5章 各類藥物的預測

  • 概要
  • 血漿來源凝血因子濃縮劑
  • 重組的凝血因子濃縮劑
  • 去氨加壓素
  • 纖維蛋白膠
  • 其他

第6章 各地區市場預測

  • 各地區市場預測概要
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 其他

第7章 定性分析

  • 波特五力分析
  • 促進要素,阻礙要素,機會

第8章 主要企業

  • Novo Nordisk A/S (Novo Nordisk)
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Bayer AG
  • CSL, LTD. (CSL)
  • Grifols S.A. (Grifols)
  • Octapharma AG (Octapharma)
  • Shire PLC (Shire)
  • Sanofi
  • Kedrion S.P.A (Kedrion)
  • 其他

第9章 結論

第10章 用語

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0237

Bleeding Disorder Treatment - our new study reveals trends, R&D progress, and predicted revenues

Where is the Bleeding Disorder Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 172-page report provides 153 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Bleeding Disorder Treatment market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 7 Bleeding Disorder Treatment Types, each forecasted at a global and regional level.

Bleeding Disorder Treatments, by Indication

  • Haemophilia A
  • Haemophilia B
  • Von Willebrand Disease (VWD)
  • Other Bleeding Disorders

Bleeding Disorder Treatments, by Drug Class

  • Plasma-derived Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • Von Willebrand Disease Factor
  • Prothrombin Complex Concentrate Factor
  • Recombinant Coagulation Factor Concentrates:
    • Factor VIII
    • Factor IX
    • Von Willebrand Disease Factor
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

image

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:

  • North America:
  • The U.S.
  • Canada
  • Mexico
  • South America:
  • Brazil
  • Argentina
  • Paraguay
  • Bolivia
  • Rest of South America
  • Europe:
  • Germany
  • France
  • The UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific:
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • Rest of Asia
  • Rest of World (RoW):
  • Middle East
  • Africa
  • Other Countries

The report also includes profiles and for some of the leading companies in the Bleeding Disorder Treatment market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and Australia in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth

Overall world revenue for Bleeding Disorder Treatment will surpass $6bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Bleeding Disorder Treatment Market report helps you

In summary, our 172-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Bleeding Disorder Treatment market with forecasts for 4 Indications and 5 Drug Classes - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 5 regional and 19 key national markets - see forecasts for the Bleeding Disorder treatment market in North America, South America, Europe, Asia-Pacific and the rest of the world. Also analysed are the national markets in the US, Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, Germany, France, the UK, Italy, Spain, Japan, China, India, Australia, Thailand, the Middle East and Africa.
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Bleeding Disorder Treatment market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain's study is for everybody needing commercial analyses for the Bleeding Disorder Treatment market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Bleeding Disorders Treatment Market Overview
  • 1.2 Market Definition
  • 1.3 Research Methodology
    • 1.3.1 Primary Research
    • 1.3.2 Secondary Research
    • 1.3.3 Market Evaluation & Forecasting Methodology
  • 1.4 Global Bleeding Disorders Treatment Market Segmentation
  • 1.5 Structure of the Report
  • 1.6 Why You Should Read This Report
  • 1.7 How this Report Delivers
  • 1.8 Key Questions Answered by This Analytical Report
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Who is This Report For?
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2. Introduction to Bleeding Disorders Treatment Market

3. Global Bleeding Disorders Treatment Market Forecast to 2027

4. Global Bleeding Disorders Treatment Market by Indication Forecast to 2027

  • 4.1 Overview
  • 4.2 Haemophilia A
  • 4.3 Haemophilia B
  • 4.4 Von Willebrand Disease (VWD)
  • 4.5 Others

5. Global Bleeding Disorders Treatment Market by Drug Class: Market Forecast to 2027

  • 5.1 Overview
  • 5.2 Plasma-derived Coagulation Factor Concentrates
    • 5.2.1 Factor VIII
    • 5.2.2 Factor IX
    • 5.2.3 Von Willebrand Disease Factor
    • 5.2.4 Factor Prothrombin Complex Concentrate
  • 5.3 Recombinant Coagulation Factor Concentrates
    • 5.3.1 Factor VIII
    • 5.3.2 Factor IX
    • 5.3.3 Von Willebrand Disease Factor
  • 5.4 Desmopressin
  • 5.5 Antifibrinolytics
  • 5.6 Fibrin Sealants
  • 5.7 Others

6. Regional Bleeding Disorders Treatment Market Forecasts to 2027

  • 6.1 Regional Bleeding Disorders Treatment Market Forecast Overview
  • 6.2 North American Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.2.1 USA Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.2.2 Canada Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.2.3 Mexico Bleeding Disorders Treatment Market Forecast 2016-2027
  • 6.3 South American Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.3.1 Brazil Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.3.2 Argentina Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.3.3 Paraguay Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.3.4 Bolivia Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.3.5 Rest of South America Bleeding Disorders Treatment Market Forecast 2016-2027
  • 6.4 European Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.1 France Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.2 Germany Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.3 UK Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.4 Spain Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.5 Italy Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.4.6 Rest of Europe Bleeding Disorders Treatment Market Forecast 2016-2027
  • 6.5 Asia-Pacific Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.1 China Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.2 Japan Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.3 India Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.4 Australia Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.5 Thailand Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.5.6 Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast 2016-2027
  • 6.6 Rest of World Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.6.1 Middle East Bleeding Disorders Treatment Market Forecast 2016-2027
    • 6.6.2 Africa Cancer Bleeding Disorders Treatment Forecast 2016-2027
    • 6.6.3 Other Countries Bleeding Disorders Treatment Market Forecast 2016-2027

7. Bleeding Disorders Treatment Market, Qualitative Analysis, 2016-2027

  • 7.1 Porter's Five Forces Analysis of the Bleeding Disorders Treatment Market 2016-2027
    • 7.1.1 Bargaining Power of Buyers (Low)
    • 7.1.2 Bargaining Power of Suppliers (Medium)
    • 7.1.3 Threat of New Entrants (Low)
    • 7.1.4 Threat of Substitute Products (Low)
    • 7.1.5 Intensity of Competitive Rivalry (High)
  • 7.2 Drivers, Restrains & Opportunities
    • 7.2.1 Drivers
    • 7.2.2 Restraints
    • 7.2.3 Opportunities

8. Leading Companies in Bleeding Disorders Treatment Market

  • 8.1 Novo Nordisk A/S (Novo Nordisk)
    • 8.1.1 Novo Nordisk: Company Overview
    • 8.1.2 Novo Nordisk: Financial Overview
    • 8.1.3 Novo Nordisk: Product Portfolio
    • 8.1.4 Novo Nordisk: Recent Developments
  • 8.2 Bristol-Myers Squibb
    • 8.2.1 Bristol-Myers Squibb: Company Overview
    • 8.2.2 Bristol Myers Squibb: Financial Overview
    • 8.2.3 Bristol-Myers Squibb: Product Portfolio
    • 8.2.4 Bristol-Myers Squibb: Recent Developments
  • 8.3 Pfizer Inc.
    • 8.3.1 Pfizer Inc.: Company Overview
    • 8.3.2 Pfizer, Inc.: Financial Overview
    • 8.3.3 Pfizer Inc.: Product Portfolio
    • 8.3.4 Pfizer Inc.: Recent Developments
  • 8.4 Bayer AG
    • 8.4.1 Bayer AG: Company Overview
    • 8.4.2 Bayer AG: Financial Overview
    • 8.4.3 Bayer AG: Product Portfolio
    • 8.4.4 Bayer AG: Recent Developments
  • 8.5 CSL, LTD. (CSL)
    • 8.5.1 CSL: Company Overview
    • 8.5.2 CSL Financial Overview
    • 8.5.3 CSL.: Product Portfolio
    • 8.5.4 CSL: Recent Developments
  • 8.6 Grifols S.A. (Grifols)
    • 8.6.1 Grifols: Company Overview
    • 8.6.2 Grifols: Financial Overview
    • 8.6.3 Grifols: Product Portfolio
    • 8.6.4 Grifols: Recent Developments
  • 8.7 Octapharma AG (Octapharma)
    • 8.7.1 Octapharma: Company Overview
    • 8.7.2 Octapharma: Financial Overview
    • 8.7.3 Octapharma: Product Portfolio
    • 8.7.4 Octapharma: Recent Developments
  • 8.8 Shire PLC (Shire)
    • 8.8.1 Shire: Company Overview
    • 8.8.2 Shire: Financial Overview
    • 8.8.3 Shire: Product Portfolio
    • 8.8.4 Shire: Recent Developments
  • 8.9 Sanofi
    • 8.9.1 Sanofi: Company Overview
    • 8.9.2 Sanofi: Financial Overview
    • 8.9.3 Sanofi: Product Portfolio
    • 8.9.4 Sanofi: Recent Developments
  • 8.10 Kedrion S.P.A (Kedrion)
    • 8.10.1 Kendrion: Company Overview
    • 8.10.2 Kedrion: Financial Overview
    • 8.10.3 Kedrion: Product Portfolio
    • 8.10.4 Kedrion: Recent Developments
  • 8.11 Other Companies in the Bleeding Disorders Treatment Market

9. Conclusions

  • 9.1 Current Leading Segments
  • 9.2 Leading Regional Markets
  • 9.3 Emerging Markets
  • 9.4 The Future of the Market?

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1. Bleeding Disorders Treatment Market Segmentation
  • Figure 2.1 Top winning Strategies of Market Players in Bleeding Disorders Market, 2014-2016
  • Figure 3.1 Bleeding Disorders Treatment, by Type, ($m), 2016-2027
  • Figure 3.2 Global Bleeding Disorders Treatment Market, by Drug Class, ($m), 2016-2027
  • Figure 4.1. Global Bleeding Disorders Treatment Market Forecast, by Type ($m) 2016-2027
  • Figure 4.2 Bleeding Disorders Treatment Market, by Type, Market Share (%), 2016
  • Figure 4.3 Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027
  • Figure 4.4 Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027
  • Figure 4.5 Global Von Willebrand Disease for Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027
  • Figure 4.6 Global Other Bleeding Disorders Treatment Market Forecast, by Geography, ($m) 2016-2027
  • Figure 5.1. Global Bleeding Disorder Treatment Market: Drug Class Segmentation
  • Figure 5.2. Global Bleeding Disorders Treatment Market, by Application, Market Share (%), 2016
  • Figure 5.3. Global Bleeding Disorders Treatment Market for Plasma-derived Coagulation Factor Concentrates Forecast, by Geography($m) 2016-2027
  • Figure 5.4. Global Bleeding Disorders Treatment Market for Recombinant Coagulation Factor Concentrates Forecast, by Geography($m) 2016-2027
  • Figure 5.5. Global Bleeding Disorders Treatment Market for Desmopressin Forecast, by Geography($m) 2016-2027
  • Figure 5.6. Global Bleeding Disorders Treatment Market for Antifibrinolytics Forecast, by Geography($m) 2016-2027
  • Figure 5.7. Global Bleeding Disorders Treatment Market for Fibrin Sealants Forecast, by Geography($m) 2016-2027
  • Figure 5.8. Global Bleeding Disorders Treatment Market for Other Drug Classes Forecast, by Geography($m) 2016-2027
  • Figure 6.1. Global Bleeding Disorders Treatment Market Forecast, by Geography, by Geography($m) 2016-2027
  • Figure 6.2. Global Bleeding Disorders Treatment Market Forecast, by Geography, Market Share (%), 2016
  • Figure 6.3. North America Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027
  • Figure 6.4. North America Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016
  • Figure 6.5. USA Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.6 Percentage of people with Haemophilia A (Statistic, 2014)
  • Figure 6.7. Canada Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.8 Mexico Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.9 South America Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027
  • Figure 6.10. South America Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016
  • Figure 6.11. Brazil Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.12. Argentina Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.13. Paraguay Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.14. Bolivia Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.15. Rest of South America Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.16. Europe Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027
  • Figure 6.17. Europe Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016
  • Figure 6.18. France Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.19. Germany Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.20. UK Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.21. Spain Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.22. Italy Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.23. Rest of Europe Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.24. Asia-Pacific Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027
  • Figure 6.25. Asia-Pacific Bleeding Disorders Treatment Market, Market Share (%), 2016
  • Figure 6.26. China Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.27. Japan Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.28. India Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.29. Australia Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.30. Thailand Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.31. Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.32. RoW Bleeding Disorders Treatment Market Forecast, by Country($m) 2016-2027
  • Figure 6.33. Rest of World Bleeding Disorders Treatment Market, by Country, Market Share (%), 2016
  • Figure 6.34. Middle East Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.35. Africa Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 6.36. Other Countries Bleeding Disorders Treatment Market Forecast ($m) 2016-2027
  • Figure 7.1 Porter's Five Forces Analysis of the Bleeding Disorders Treatment Market
  • Figure 9.1 World Bleeding Disorders Treatment, by Type, ($m), 2016-2027
  • Figure 9.2 World Bleeding Disorders Treatment, by Drug Type, ($m), 2016-2027
  • Figure 9.3. World Bleeding Disorders Treatment, by Geography, ($m), 2016-2027

List of Tables

  • Table 2.1 Global Demographics: People suffering from haemophilia and other bleeding disorders
  • Table 3.1. Global Bleeding Disorders Treatment Market Forecast ($m, AGR%, CAGR%) 2016-2027
  • Table 4.1 Bleeding Disorders Treatment Market, by Type, Forecast ($m, AGR%, CAGR%) 2016-2027
  • Table 4.2.Key Haemophilia A Drugs approved by FDA
  • Table 4.3. Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.4. Global Haemophilia A for Bleeding Disorders Treatment Market Forecast, by Geography, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.5.Key Haemophilia B Drugs approved by FDA
  • Table 4.6. Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.7. Global Haemophilia B for Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 4.8. Global Von Willebrand Disease for Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.9. Global Von Willebrand Disease for Bleeding Disorders Treatment Market, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 4.10. Global Other Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.11. Global Other Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.1. Global Blood Disorders Treatment Market, by Drug Class($m, AGR%, CAGR%) 2016-2027
  • Table 5.2. Types of Monoclonal Antibodies
  • Table 5.3. Global Bleeding Disorders Treatment Market for Plasma-Derived Coagulation Factor Concentrates, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.4. Global Bleeding Disorders Treatment Market for Plasma-derived Coagulation Factor Concentrates, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.5. Global Blood Disorders Treatment Market for Recombinant Coagulation Factor Concentrates ($m, AGR%, CAGR%) 2016-2027
  • Table 5.6. Global Bleeding Disorders Treatment Market for Recombinant Coagulation Factor Concentrates, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.7. Global Blood Disorders Treatment Market for Desmopressin ($m, AGR%, CAGR%) 2016-2027
  • Table 5.8. Global Bleeding Disorders Treatment Market for Desmopressin, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.9 Global Blood Disorders Treatment Market for Antifibrinolytics Concentrates ($m, AGR%, CAGR%) 2016-2027
  • Table 5.10. Global Bleeding Disorders Treatment Market for Antifibrinolytics by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.11 Global Blood Disorders Treatment Market for Fibrin Sealants ($m, AGR%, CAGR%) 2016-2027
  • Table 5.12. Global Bleeding Disorders Treatment Market for Fibrin Sealants, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.13. Global Blood Disorders Treatment Market for Others ($m, AGR%, CAGR%) 2016-2027
  • Table 5.14. Global Bleeding Disorders Treatment Market for Others, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 6.1. Global Bleeding Disorders Treatment Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 6.2. North America Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 6.3. USA Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.4. Canada Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.5. Mexico Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.6. South America Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 6.7. Brazil Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.8. Argentina Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.9. Paraguay Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.10. Bolivia Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.11. Rest of South America Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.12. European Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 6.13. France Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.14. Germany Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.15. UK Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.16. Spain Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.17. Italy Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.18. Rest of European Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.19. Asia-Pacific Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 6.20. China Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.21. Japan Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.22. India Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.23. Australia Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.24. Thailand Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.25. Rest of Asia-Pacific Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.26. Rest of World Bleeding Disorders Treatment Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 6.27. Middle East Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.28. Africa Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.29. Other Countries Bleeding Disorders Treatment Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 8.1. Novo Nordisk: Financial Overview
  • Table 8.2. Novo Nordisk: Financial Overview
  • Table 8.3. Novo Nordisk: Product Portfolio
  • Table 8.4. Novo Nordisk: Recent Developments
  • Table 8.5. Bristol-Myers Squibb: Company Overview
  • Table 8.6. Bristol Myers Squibb: Financial Overview
  • Table 8.7. Bristol-Myers Squibb: Product Portfolio
  • Table 8.8. Pfizer Inc.: Company Overview
  • Table 8.9. Pfizer, Inc.: Financial Overview
  • Table 8.10. Pfizer Inc.: Product Portfolio
  • Table 8.11. Pfizer Inc.: Recent Development
  • Table 8.12. Bayer AG: Company Overview
  • Table 8.13. Bristol Myers Squibb: Financial Overview
  • Table 8.14. Bayer AG: Product Portfolio
  • Table 8.15. Bayer AG: Recent Development
  • Table 8.16. CSL Company Overview
  • Table 8.17. CSL: Financial Overview
  • Table 8.18. CSl: Product Portfolio
  • Table 8.19. CSL: Recent Development
  • Table 8.20. Grifols: Company Overview
  • Table 8.21. Grifols: Financial Overview
  • Table 8.22 Grifols: Product Portfolio
  • Table 8.23. Octapharma: Company Overview
  • Table 8.24. Octapharma: Financial Overview
  • Table 8.25 Octapharma: Product Portfolio
  • Table 8.26. Octapharma: Recent Development
  • Table 8.27. Shire: Company Overview
  • Table 8.28. Shire: Financial Overview
  • Table 8.29. Shire: Product Portfolio
  • Table 8.30. Shire: Recent Development
  • Table 8.31. Sanofi: Company Overview
  • Table 8.32. Sanofi: Financial Overview
  • Table 8.33. Sanofi: Product Portfolio
  • Table 8.34. Kedrion: Company Overview
  • Table 8.35. Kedrion: Financial Overview
  • Table 8.36. Kedrion: Product Portfolio
  • Table 8.37. Kedrion: Recent Development
  • Table 8.38 Other Companies for Bleeding Disorders Treatment Market
  • Table 9.1 Global Demographics: People suffering from haemophilia and other bleeding disorders

Companies Listed

  • Abbott Laboratories
  • AbbVie, Inc.
  • Aetna, Inc.
  • Alkermes Plc
  • Amarin Corp. Plc
  • Amgen, Inc.
  • Array BioPharma, Inc.
  • Associates Of Cape Cod Inc.
  • Astex Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bayer Corporation
  • Bayer HealthCare AG
  • Bayer Schering Pharma Aktiengesellschaft
  • BioMarin Pharmaceutical, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Co.
  • Cardax, Inc.
  • Cardinal Health, Inc.
  • Ceapro, Inc.
  • Celgene Corp.
  • Centene Corp.
  • Cephalon, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CK Life Sciences International (Holdings), Inc.
  • Cornerstone Research & Development Inc.
  • CTI BioPharma Corp.
  • Domain Therapeutics SA
  • Emd Millipore Corporation
  • Emd Serono Inc.
  • Endo International Plc
  • Evotec AG
  • GlaxoSmithKline Plc
  • Janssen Biotech, Inc.
  • JHL Biotech, Inc.
  • Johnson & Johnson
  • Laboratoire Theramex
  • Lonza Group AG
  • McKesson Corp.
  • Merck KGaA
  • MorphoSys AG
  • Motif Bio Plc
  • Myrexis, Inc.
  • NBTY, Inc.
  • Neptune Technologies & Bioresources, Inc.
  • Nexvet Biopharma PLC
  • Nordion Inc
  • Novartis AG
  • Opexa Therapeutics, Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Owens & Minor, Inc.
  • Panacos Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Pharma Mar SA
  • Premier Healthcare Alliance L.P.
  • Quanterix Corp.
  • Samsung BioLogics Co., Ltd.
  • Sangers (Northern Ireland) Limited
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Taiho Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • UnitedHealth Group, Inc.
  • Verastem, Inc.
  • Vertex Pharmaceuticals, Inc.
  • Windtree Therapeutics, Inc.
  • Zogenix, Inc.

Organizations Mentioned in the Report

  • American College of Nutrition
  • Australian Institute of Health and Welfare
  • European Medicines Agency
  • Health Canada
  • International Medical Corps
  • National Cancer Institute
  • National Health Service
  • The American Society of Clinical Oncology Inc
  • The Feinstein Institute for Medical Research
  • The National Institute for Health and Clinical Excellence
  • United States Department of Health & Human Services
  • World Health Organization
Back to Top